NCT00308178已完成不适用
Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study
Harold J. Burstein, MD, PhD6 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2006年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 66
- 试验地点
- 6
- 主要终点
- To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.
研究概览
简要总结
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor.
详细描述
- Patients will receive regular chemotherapy every 2 weeks for up to 8 cycles (approximately 16 weeks total)of treatment. During the first four cycles patients will be treated with Adriamycin and Cytoxan, and for the second four cycles they will be treated with Abraxane.
- Patients will be taught to give themselves injections with either short or long acting G-CSF as prescribed by their doctor for the first four cycles of chemotherapy. During the last four cycles (while the patient is taking Abraxane) they will not receive G-CSF unless they have low blood counts.
- If the patient has HER-2 positive breast cancer, they will also receive 52 weeks of Herceptin as part of standard cancer care and will begin to receive Herceptin at the same time they begin Abraxane (after 4 cycles of adriamycin and cytoxan treatment).
- This study involves a series of Quality of Life Questionnaires that will be completed prior to beginning study treatment, then again at 2 months, 4 months, 6 months, and 1 year after starting study treatment.
- The following tests and procedures will be performed at the time periods specified. Cycle 1-4 Day 1: Physical exam, vital signs, and blood tests. Cycle 5 Day 1: Physical exam, vital signs, blood tests, RVG (measurement of heart function) and questionnaire. Cycle 6 & 7 Day 1: Physical exam, vital signs, and blood tests. Cycle 8 Day 1: physical exam, vital signs, blood tests, questionnaire. Follow-up (6 months and 1 year after cycle 1 day 1): questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed breast cancer, with clinical stage I, II, or III disease
- •Must register at the beginning of adjuvant or neoadjuvant chemotherapy
- •18 years of age or older
- •ECOG performance status of 0 or 1
- •Normal organ and marrow function
排除标准
- •Previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason
- •Pregnant or nursing
- •Receiving any other investigational agents
- •Patients with Stage IV breast cancer
- •Current grade II or greater peripheral neuropathy or prior history of grade II or greater neuropathy
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Immune deficiency when treated with marrow-suppressive therapy or HIV-positive patients receiving anti-retroviral therapy
- •Patients with sickle cell disease
- •Known history of hyperviscosity syndrome
- •Patients on lithium
结局指标
主要结局
To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.
时间窗: 2 years
次要结局
- To evaluate the feasibility of administering Abraxane on a dose dense schedule without G-CSF support(2 years)
- to estimate the percentage of patients with various grades of hematologic toxicity, neurotoxicity, and other non-hematologic toxicity associated with dose-dense Abraxane(2 years)
- to evaluate quality of life.(2 years)
研究者
Harold J. Burstein, MD, PhD
Associate Professor of Medicine
Dana-Farber Cancer Institute
研究点 (6)
Loading locations...
相似试验
Unknown
1 期
Abraxane and Temodar Plus Genasense in Advanced MelanomaMelanomaNCT00409383Genta Incorporated28
已完成
1 期
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic AdenocarcinomaPancreatic NeoplasmsAdenocarcinomaPancreatic CancerNCT01161186University of California, San Francisco15
已完成
2 期
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine TherapyPancreatic CancerNCT00691054University of Miami20
Unknown
2 期
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.Breast CancerNCT00777673University of Tennessee Cancer Institute60
已完成
2 期
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerRecurrent Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal CarcinomaNCT00499252Gynecologic Oncology Group51